How Much Does Semaglutide Cost for Weight Loss in Ireland?

Semaglutide is the active ingredient inside two branded pens you will see discussed constantly in Ireland right now: Ozempic and Wegovy, both manufactured by Novo Nordisk. They contain the same molecule, but they are licensed for different purposes, and that distinction matters both medically and financially. Ozempic is authorised in Ireland and the wider EU for the treatment of type 2 diabetes, where it helps lower blood sugar and, as a secondary effect, tends to reduce appetite and body weight. Wegovy is authorised specifically for chronic weight management in adults with obesity, or with overweight plus a weight-related health condition, at a higher maintenance dose of 2.4 mg.

Because Ozempic reached Irish pharmacies first and built a reputation for weight loss as a side effect of diabetes treatment, a great many prescriptions for weight management purposes have historically been written for Ozempic off-label rather than for Wegovy on-label. This is legal, since doctors in Ireland can prescribe an authorised medicine for an unlicensed use where they judge it clinically appropriate, but it is worth knowing which drug you are actually being prescribed and why, since the two have different dosing ceilings and different official indications.

Both medicines are authorised, prescription-only medicines with a full HPRA marketing authorisation on file, which is a meaningfully different regulatory position from the unlicensed peptides sometimes discussed in the same online spaces. That authorisation means the manufacturing, labelling, and safety monitoring have been reviewed by regulators, and it is also why HPRA has repeatedly warned the public about counterfeit and illegally imported semaglutide-type pens sold outside the legitimate pharmacy system, which carry real risks of contamination and incorrect dosing.

Prices vary between pharmacies and shift with supply, but the ranges have settled into a fairly consistent pattern. For Ozempic, expect to pay roughly €130 to €160 for the starter 0.25 mg dose over a 28-day supply, rising to around €140 to €185 for the standard 0.5 mg to 1 mg doses, and up to €175 to €210 for the highest 2 mg dose. For Wegovy, the titration phase, covering the 0.25 mg to 1 mg doses used in the first few months, typically costs €180 to €260 per month, while the 1.7 mg and 2.4 mg maintenance doses used long-term run to roughly €260 to €340 per month.

These figures reflect private pharmacy pricing in Ireland as of the second half of 2026 (prices last checked September 2026) and will move over time as supply stabilises and competition between pharmacies increases, so treat them as a planning range rather than a fixed quote from any specific provider. Ask your own pharmacist for their current price before committing to a course, since even a modest difference per pen adds up considerably over months of treatment.

A point worth flagging clearly: Ozempic is not currently reimbursed by the HSE for weight-loss use, and the Drug Payment Scheme's monthly spending cap, which limits what a GMS-eligible household pays for reimbursable medicines, does not apply here either. Semaglutide prescribed for weight management is a private, out-of-pocket cost for the vast majority of people in Ireland, regardless of medical card status.

Both Ozempic and Wegovy are dosed on an escalating schedule, starting low and increasing every four weeks to reduce gastrointestinal side effects and allow the body to adjust. For Wegovy specifically, this titration period typically runs sixteen to twenty weeks before you reach the target maintenance dose, and because higher-strength pens cost more, your monthly bill rises in step with the dose.

As a worked example using the ranges above, someone starting Wegovy might pay around €185 for their first month at the lowest dose, and by the time they reach the 2.4 mg maintenance dose several months later, they could be paying closer to €310 a month. Added together across a six-month course, that escalation pattern typically comes to somewhere in the region of €1,500 to €1,900 in total, though the exact figure depends on how quickly you titrate and which pharmacy you use.

This is one of the most commonly misunderstood parts of budgeting for semaglutide: people often price the treatment based on the starter dose alone, only to be caught out when the monthly cost climbs substantially over the following months. Build the full escalation into your budget from the outset rather than assuming the first month's price will hold.

There are three broad routes to a semaglutide prescription in Ireland, and none of them let you skip the assessment stage. The first, and generally the most sensible, is through your own GP, who already knows your medical history, your other medications, and any conditions that might make semaglutide unsuitable. Many GPs are now comfortable prescribing GLP-1 medications for weight management where clinically appropriate, though not every practice offers this, so it is worth asking directly.

The second route is a registered online prescribing service. Several Irish-registered platforms offer a video or questionnaire-based consultation with an Irish doctor, typically for a fee in the region of €20 to €30, after which an approved prescription is sent directly to a partner pharmacy for dispensing. This route can be faster than waiting for a GP appointment, but it is worth checking that the service is genuinely Irish-registered and uses licensed prescribers rather than an offshore operation with looser oversight.

The third route is a private weight-management or metabolic health clinic offering a more structured programme, often bundling the prescription with dietitian support, blood monitoring, and follow-up consultations. This tends to cost more overall but suits people who want more comprehensive support than a single prescribing consultation provides. Whichever route you choose, a genuine assessment of your health history, current medications, and suitability should always come first; any service willing to dispense semaglutide without that step is not one to use.

Clinical eligibility for semaglutide as a weight-management medicine generally follows the same criteria used across the EU: a body mass index of 30 or above, classed as obesity, or a BMI of 27 to 29.9 alongside at least one weight-related condition such as type 2 diabetes, high blood pressure, high cholesterol, obstructive sleep apnoea, cardiovascular disease, or polycystic ovary syndrome. A prescriber will also screen for contraindications before agreeing to prescribe, which is one of the reasons a proper consultation matters rather than a quick online form.

The HSE's position on funding is more restrictive than many people expect. Semaglutide for type 2 diabetes, prescribed as Ozempic, is reimbursable under the GMS and Drug Payment Scheme in the normal way for an approved diabetes medicine. But semaglutide prescribed specifically for weight management is not covered, and falls outside the Drug Payment Scheme's monthly spending cap entirely. The HSE does operate a managed access protocol for a related GLP-1 medicine, liraglutide (marketed as Saxenda), for weight management in specific circumstances, which shows the reimbursement pathway exists in principle for this drug class, but as things stand semaglutide for obesity remains a private-pay medicine for the great majority of patients in Ireland.

This matters practically because it means medical card status generally will not reduce your costs here, unlike with most other prescribed medicines. Anyone budgeting for a course of treatment should plan on paying the full private price, and should factor in that private health insurance in Ireland also typically excludes weight-loss medication from cover.

The strongest evidence behind semaglutide's effect on body weight comes from a large randomised, double-blind, placebo-controlled trial known as STEP 1, published in the New England Journal of Medicine in 2021. Researchers enrolled 1,961 adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition, none of whom had diabetes, and randomly assigned them in a two-to-one ratio to 68 weeks of once-weekly 2.4 mg semaglutide or placebo, both alongside lifestyle support.

The results were substantial: participants on semaglutide lost an average of 14.9 percent of their body weight, compared with 2.4 percent on placebo, an estimated treatment difference of 12.4 percentage points. In absolute terms that was a mean loss of 15.3 kg on semaglutide versus 2.6 kg on placebo. More than two-thirds of the semaglutide group lost 10 percent or more of their body weight, compared with just 12 percent of the placebo group. This is one randomised trial rather than a body of independently replicated evidence, so it should be read as one strong RCT finding rather than as settled consensus, though its results have since been broadly consistent with real-world prescribing experience.

One detail worth being transparent about: the STEP 1 trial was funded by Novo Nordisk, the manufacturer of semaglutide, which is a relevant conflict of interest to note even though the trial was conducted to the rigorous double-blind, placebo-controlled standard expected of a major clinical trial published in a leading peer-reviewed journal. The same trial also recorded its side-effect data carefully, and that is worth reading before you commit to a course.

Nausea and diarrhoea were the most common adverse events in the STEP 1 trial, typically transient and mild to moderate, generally settling as the body adjusts to each new dose. But they were not trivial for everyone: 4.5 percent of participants on semaglutide discontinued treatment specifically because of gastrointestinal side effects, compared with 0.8 percent on placebo. Vomiting, constipation, and abdominal discomfort are also commonly reported, particularly around dose increases.

More serious but rarer concerns include pancreatitis and gallbladder problems, both of which prescribers screen for before starting treatment and monitor for afterwards. Semaglutide is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, a precaution that stems from thyroid C-cell tumours observed in rodent studies; this effect has not been confirmed in humans, but it is the reason the medicine's licence carries that specific exclusion. It is also not recommended in pregnancy, while breastfeeding, or in people with a history of severe gastrointestinal disease.

Because of these risks, a genuine medical assessment before starting, and some level of follow-up during treatment, is not a bureaucratic formality but a real safety step. Anyone sourcing semaglutide-type products outside the legitimate Irish pharmacy system, including online sellers not registered with the Pharmaceutical Society of Ireland, is taking on the added risk of counterfeit or contaminated product, a problem HPRA has specifically warned about.

Putting the pieces together, a realistic six-month course of Wegovy, from the lowest titration dose through to a stable maintenance dose, will typically cost somewhere between €1,500 and €2,000 in medication alone at current Irish pharmacy prices (prices last checked September 2026), before adding consultation fees, any required blood tests, and follow-up appointments. Ozempic used off-label for weight management tends to sit at the lower end of that range, since its dosing ceiling is lower than Wegovy's, but the same principle of rising cost with rising dose still applies.

Most people considering semaglutide for weight loss in Ireland should treat it as an ongoing, several-hundred-euro-a-month private expense for as long as they remain on treatment, rather than a one-off cost. Weight regain after stopping GLP-1 medications is common, which is a genuine long-term financial and clinical consideration worth discussing with your prescriber before you start, alongside the lifestyle changes that these medicines are licensed to be used alongside rather than instead of.

If cost is the deciding factor, it is worth having a direct conversation with your GP about whether you meet the criteria for Ozempic under a diabetes indication, if that applies to you, since that route carries normal GMS and Drug Payment Scheme reimbursement in a way the weight-management indication currently does not.